Navigation Links
IC Sciences Launches ICS Alliance to Advance Development and Adoption of Informatics Instruments for Next Generation Healthcare
Date:4/2/2008

BOSTON, April 2, 2008 /PRNewswire/ -- IC Sciences Corporation announced today the launch of the company's alliance membership program, ICS Alliance (http://www.icsciencesalliance.com). During the past two years, IC Sciences has been developing components for the newly launched membership program, such as scientific tools, industry products, and market case studies covering healthcare informatics instruments for professional, consumer, and therapeutics medical market sectors. The Alliance program serves as a collaborative nexus of clinicians, healthcare executives, allied professionals, researchers, developers, and other users of these instruments.

Alliance members receive value through a range of program offerings, consisting of a leadership network of experts (Event Series), strategic market analysis and research reports, digital intelligence briefings, and a members-only virtual portal community. Peter M. Nicholas Jr., Founder and Chief Executive Officer of IC Sciences, remarked, "We envision the ICS Alliance as a 'central exchange station' of multi-perspective and multi-sector ideas, tools, practices, and contacts concerning healthcare informatics. We are pleased to be in our second year of the Event Series, which has hosted 18 events and has featured guest hosts such as Clayton Christensen of Harvard Business School, Jonathan Bush of AthenaHealth, and Charlie Baker of Harvard Pilgrim Health. We look forward to inviting the nation's e-health executives, clinicians, and medical informatics leaders to join our membership in 2008 and beyond."

Alliance members, who currently include Revolution Health, AthenaHealth, PatientsLikeMe, and Blue Cross Blue Shield of Massachusetts, joined the program because of a collective interest in understanding this rapidly evolving field, as well as how new sciences and technologies are improving the effectiveness, value, and experience of healthcare. These informatics instruments are used by clinicians, patients, consumers, payers, and therapeutics manufacturers in myriad contexts and applications, including patient engagement, collective intelligence among clinician or patient peers, clinical performance management, and therapeutic product support.

To learn more about ICS Alliance and membership benefits and opportunities, visit http://www.icsciencesalliance.com.

About IC Sciences Corporation

IC Sciences Corporation is a closely held, private organization pioneering in the medical information sciences and informed clinical technology markets. IC Sciences Corporation, through its operating companies, is creating the world's most comprehensive and broadly based developer of intelligent informatics systems and digital informatics instruments for the professional, consumer, and therapeutics medical markets. Our core business is about employing the Internet and related technology platforms to support the delivery of informed clinical systems that optimally impact patient care through the science and the art of contextually differentiated informing. For more information, please visit: http://www.ICSciences.com

Contact:

IC Sciences Corporation

One Joy Street Boston, MA 02108

publicrelations@icsciences.com

1-800-603-1420


'/>"/>
SOURCE IC Sciences Corporation
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
2. Selection of Development Candidate Triggers $0.5 Million Milestone Payment to Ardea Biosciences, Inc.
3. ImmuneRegen BioSciences Files 8-K that Highlights Enclosed Shareholder Letter Discussing Recent Achievements and Outlook
4. Advanced Life Sciences Announces Receipt of Nasdaq Staff Letter
5. VisEn Medical Files Action to Invalidate New Caliper Life Sciences Patent
6. ONCOSCIENCE AG, THE EUROPEAN PARTNER OF YM BIOSCIENCES, ANNOUNCES COMPLETION OF PATIENT ENROLLMENT IN PHASE III BRAIN CANCER TRIAL OF NIMOTUZUMAB
7. Pressure BioSciences, Inc. Reports Second Quarter 2007 Financial Results and Provides Business Update
8. Intellect Neurosciences, Inc. to Present Data on Alzheimers Vaccine at 13th International Congress of Immunology Conference
9. YM BIOSCIENCES, EUROPEAN PARTNER, ONCOSCIENCE AG, ANNOUNCES INITIATION OF ADVANCED NIMOTUZUMAB TRIALS IN ADULT GLIOMA AND PANCREATIC CANCER
10. Advanced Cell Technologys Dr. Robert Lanza Makes List of 100 Most Inspiring People in the Life-Sciences Industry
11. The Pittsburgh Life Sciences Greenhouse Adds New Companies to its Investment Portfolio
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... , Dec. 8, 2016  Biotheranostics today announced ... role of the Breast Cancer Index (BCI) in ... cancer are most at-risk for disease recurrence and ... results from three studies advancing the understanding of ... to tumor biology and inform decisions related to ...
(Date:12/8/2016)... USA, and CARDIFF, UK (PRWEB) , ... December ... ... with very high precision light to control cells — optogenetics — is key ... the current state of the art, spatially patterned light projected via free-space optics ...
(Date:12/8/2016)... -- Oxford Gene Technology (OGT), The ... range with the launch of the SureSeq myPanel™ NGS Custom ... in familial hypercholesterolemia (FH). The panel delivers single nucleotide variation ... small panel and allows customisation by ,mix and match, of ... LDLR , P C SK9 , ...
(Date:12/8/2016)... ... December 08, 2016 , ... ... exceptionally efficient human mesenchymal stem/stromal cell (hMSC) expansion medium. This single ... engineered to radically streamline culture processes, minimize processing time, significantly decrease production ...
Breaking Biology Technology:
(Date:12/7/2016)... According to a new market research report "Emotion Detection ... Voice Recognition), Service, Application Area, End User, And Region - Global Forecast to ... 6.72 Billion in 2016 to USD 36.07 Billion by 2021, at a Compound ... ... MarketsandMarkets Logo ...
(Date:12/6/2016)... WARSAW, Ind. , Dec. 6, 2016  Zimmer Biomet ... that it has priced an offering of €500.0 million principal ... €500.0 million principal amount of its 2.425% senior unsecured notes ... is expected to occur on December 13, 2016, subject to the ... on an annual basis. ...
(Date:12/2/2016)... The report "Biometric Vehicle Access ... (Iris Recognition System), Vehicle Type (Passenger Car, Battery ... 2021", published by MarketsandMarkets, the market is estimated ... is projected to grow to USD 854.8 Million ...      (Logo: http://photos.prnewswire.com/prnh/20160303/792302) ...
Breaking Biology News(10 mins):